Home » Tenders » Americas » Canada » Molecular Assay for Drug Resistant Tb Testing Tender, Canada - 101345046

Molecular Assay for Drug Resistant Tb Testing Tender, Canada - 101345046

PUBLIC HEALTH ONTARIO has floated a tender for Molecular Assay for Drug Resistant Tb Testing. The project location is Canada and the tender is closing on 21 May 2024. The tender notice number is tender_18543, while the TOT Ref Number is 101345046. Bidders can have further information about the Tender and can request the complete Tender document by Registering on the site.

Procurement Summary

Country : Canada

Summary : Molecular Assay for Drug Resistant Tb Testing

Deadline : 21 May 2024

Other Information

Notice Type : Tender

TOT Ref.No.: 101345046

Document Ref. No. : tender_18543

Competition : ICB

Financier : Self Financed

Purchaser Ownership : Public

Tender Value : Refer Document

Purchaser's Detail

Name :Login to see tender_details

Address : Login to see tender_details

Email : Login to see tender_details

Tender Details

PHO believes that the following procurement qualifies as a sole source or single source procurement. The purpose of this Advanced Contract Award Notice (ACAN) is to determine if there are other proponents capable of meeting the requirements of the procurement for the following supplies for PHO.

Vendor: Becton Dickinson Canada Inc

Product: BD Max MDR-TB Assay

Purpose: A Health Canada approved assay for the detection of drug resistant Mycobacterium tuberculosis. The drug resistance targets sought as part of this assay are for isoniazid and rifampin.

PHO has a requirement a commercial Health Canada approved molecular assay for detection of drug resistant Mycobacterium tuberculosis, with drug resistance targets of isoniazid and rifampin. Recent changes to the Canadian Tuberculosis Standards require a test with a short turnaround time to determine prompt treatment for individuals with M. tuberculosis detected by molecular assays. As such, PHO requires supply of an assay which is capable of detecting multidrug resistant tuberculosis from clinical specimens, as well as culture isolates.

PHO believes that the BD MAx MDR-TB Assay is the only commercial Health Canada approved assay for this use capable of detecting isoniazid and rifampin resistant M. tuberculosis.

PHO intends to award a 5 year term contract (comprised of 2 firm years and 3 one-year options) to Becton Dickinson for the products described above.

This request does not constitute a call...
Summary information
Language(s) : French, English
Contract duration : 24 month(s)
Procurement method : Competitive – Open Bidding
Closing date and time : 2024/05/21 11:00 EDT
Last amendment date : 2024/05/16